Form 4: Accuray Director Mika Nishimura Granted 56,603 RSUs

Accuray Inc. Director Mika Nishimura was granted 56,603 Restricted Stock Units, aligning her interests with shareholders.

Summary

• Mika Nishimura, a Director of Accuray Inc. (ARAY), acquired 56,603 Restricted Stock Units (RSUs).
• The transaction date for the RSU grant was November 28, 2025.
• Each RSU represents a contingent right to receive one share of Accuray's common stock.
• The RSUs were acquired at a price of $0, which is typical for equity grants.
• The 56,603 RSUs will vest 100% on November 13, 2026.
• Following this transaction, Mika Nishimura beneficially owns 56,603 derivative securities (RSUs) directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director receiving equity compensation aligns their interests with shareholders, which is generally viewed favorably. However, it's a routine transaction and not indicative of significant operational or financial news.

Positives

• The grant of Restricted Stock Units to a director aligns management's long-term interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• Equity compensation is a standard practice to attract and retain qualified directors and executives.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedule of the granted Restricted Stock Units.

Industry Context

The grant of Restricted Stock Units to a director is a common form of equity compensation across various industries, including the medical technology sector where Accuray operates. This practice is widely used to incentivize long-term performance and retain key personnel by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of director compensation is a standard practice in publicly traded companies, including those in the medical device and healthcare technology sectors like Accuray. Companies such as Intuitive Surgical (ISRG) and Varian Medical Systems (now Siemens Healthineers) frequently utilize similar equity-based incentives for their non-employee directors and executives.
• The vesting schedule, with a 100% vest on a future date, is typical for time-based RSU grants, designed to encourage long-term commitment and alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be seen as a positive for shareholders, as it further aligns the director's financial interests with the company's long-term stock performance.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The 56,603 Restricted Stock Units will vest on November 13, 2026, at which point Mika Nishimura will receive shares of Accuray common stock.

Key Dates

Keywords

Accuray Inc., ARAY, Restricted Stock Units, RSU grant, insider transaction, director compensation, equity compensation, beneficial ownership